REVELATION BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
REVELATION BIOSCIENCES, INC. (REVB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 2.90% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2023-03-30
- REVELATION BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 2.90%.
- REVELATION BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -2.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2022-12-31 | 2.90% 10-K · filed 2023-03-30 |
| 2021-12-31 | -2.30% 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |